Menu

Infographic: Evolving Virulence

Tracking the myxoma virus in the wild rabbit populations of Australia has yielded insight into how pathogens and their hosts evolve.

Sep 30, 2017
Andrew F. Read and Peter J. Kerr

When a pathogen jumps species, it is often highly lethal in its new host. But a quick kill does not make for continued transmission; the host must survive long enough to pass the pathogen on to additional victims. Thus, under natural conditions, a newly emergent, highly lethal pathogen that kills very rapidly is expected to evolve lower virulence. At the same time, however, the host species is evolving resistance to the infection, which then provides an environment for increasing pathogen virulence. Could humans be creating a similar environment by vaccinating or breeding our farm animals to resist disease?

Wild rabbit populations in Australia declined dramatically in the early 1950s after the release of the myxoma virus, which caused a fatal disease called myxomatosis. Slowly, the populations started to rebound, though they never fully recovered.

To track the myxoma virus (MYXV) as it devastated the invasive rabbit populations of Australia, researchers conducted what are known as common garden experiments, testing the effects of the evolving viral strains on laboratory rabbits, as well as the effects of a standard virus on different samples of rabbits in the wild over time.

When MYXV first infected the Australian rabbit population in 1950, it caused a severe disease known as myxomatosis that killed more than 99 percent of its victims. Natural selection favored strains with reduced lethality and therefore longer infectious periods. Within a few years, circulating viruses had fatality rates between 95 percent and less than 50 percent.

Meanwhile, the rabbits were evolving resistance to the viral infection, though the protection was not complete, allowing the virus to continue evolving.

Host resistance likely decreased the virus’s transmission rate, thus setting the stage for the selection of more virulent strains. Sometime between the mid-1970s and the early 1980s, strains arose that massively suppressed the cellular inflammatory response of laboratory rabbits. In wild rabbits, the combination of host resistance and increased viral virulence resulted in typical myxomatosis presentation, but when naive rabbits were exposed to the new viral strains, bacterial infections bloomed in their immunosuppressed bodies, killing nearly all of the hosts before they developed the classic disease.

Read the full story.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.